Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Dakin

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Health and Quality of Life Outcomes|September 10, 2024
How are maternal and fetal outcomes incorporated when measuring benefits of interventions in pregnancy? Findings from a systematic review of cost-utility analysesLucy Abel, Helen Dakin, Ting Cai, et al.
Journal of Medical Economics|August 22, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 2, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Health and Quality of Life Outcomes|August 2, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
International Journal of Technology Assessment in Health Care|August 4, 2015
PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENTStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Clinical Drug Investigation|August 1, 2008
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspectiveHiltrud Liedgens, Nadine Hertel, Anja Gabriel, et al.
Bone & Joint Open|November 15, 2022
Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation modelHelen Dakin, Ines Rombach, Melina Dritsaki, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 20, 2018
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS StatementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Applied Health Economics and Health Policy|August 2, 2015
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS StatementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Pharmacoeconomics|August 2, 2015
The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and ElaborationStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Health and Quality of Life Outcomes|September 10, 2024
How are maternal and fetal outcomes incorporated when measuring benefits of interventions in pregnancy? Findings from a systematic review of cost-utility analysesLucy Abel, Helen Dakin, Ting Cai, et al.
Journal of Medical Economics|August 22, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 2, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: the MAPS statementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Health and Quality of Life Outcomes|August 2, 2015
Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
International Journal of Technology Assessment in Health Care|August 4, 2015
PREFERRED REPORTING ITEMS FOR STUDIES MAPPING ONTO PREFERENCE-BASED OUTCOME MEASURES: THE MAPS STATEMENTStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Clinical Drug Investigation|August 1, 2008
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspectiveHiltrud Liedgens, Nadine Hertel, Anja Gabriel, et al.
Bone & Joint Open|November 15, 2022
Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation modelHelen Dakin, Ines Rombach, Melina Dritsaki, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|April 20, 2018
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS StatementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Applied Health Economics and Health Policy|August 2, 2015
Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS StatementStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Pharmacoeconomics|August 2, 2015
The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and ElaborationStavros Petrou, Oliver Rivero-Arias, Helen Dakin, et al.
Pageof 6